Healthcare

Mylan CEO stresses market-based solution to drug pricing

By Paige Winfield Cunningham
Published January 11, 2017 6:32pm ET
Add Washington Examiner on Google
Mylan CEO stresses market-based solution to drug pricing
EpiPen maker says ensuring annual increases are below 10 percent, as some have suggested, isn't the answer. (AP Photo/Rich Pedroncelli) | Rich Pedroncelli

SAN FRANCISCO — Mylan’s CEO gave a measured response to President-elect Trump’s promise Wednesday morning to crack down on high drug prices.

Heather Bresch, who spent the last half of 2016 under fire for raising the price of the company’s EpiPen allergy shot 400 percent, said she would have to see the entire picture of what Trump is suggesting before pronouncing judgment.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Affordable Care Act Donald Trump Epipen Minusextra Paige Winfield Cunningham Pharmaceutical Industry San Francisco